Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Date publication

mai 2026

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AME Shanti

Tous les auteurs :
Nicolini FE, Etienne G, Huguet F, Charbonnier A, Roth-Guépin G, Escoffre-Barbe M, Dubruille V, Johnson-Ansah H, Rousselot P, Legros L, Parry A, Roy L, Coiteux V, Lenain P, Ianotto JC, Doublet C, Orvain C, Simonet-Boissard M, Chrétien ML, Penot A, Meunier M, Amé S, Hermet E, Quittet P, Lapusan S, Schwiertz V, Cayuela JM, Mauté C, Réa D, Morisset S, Mahon FX, Dulucq S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42069411

Résumé

Second generation tyrosine kinase inhibitors (TKIs) have improved response rates in patients with chronic phase chronic myeloid leukaemia (CP-CML). Phase 2 trials demonstrated increased deep molecular response rates when combining second generation TKIs with pegylated interferon alfa (Peg-IFN). This trial aimed to evaluate the efficacy and the safety of combining nilotinib with Peg-IFN alfa-2a in patients with newly diagnosed CP-CML.

Mots clés

Humans, Male, Female, Interferon-alpha, therapeutic use, Middle Aged, Pyrimidines, therapeutic use, Polyethylene Glycols, therapeutic use, Adult, Recombinant Proteins, therapeutic use, Aged, France, Leukemia, Myeloid, Chronic-Phase, drug therapy, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Treatment Outcome, Protein Kinase Inhibitors, therapeutic use, Fusion Proteins, bcr-abl, genetics

Référence

Lancet Haematol. 2026 05;13(5):e315-e326